We don’t have a webinar scheduled at the moment, but more exciting sessions are on the way! Check back soon for details, or sign up for our newsletter to be notified when new webinars are announced.

Sign up for our newsletter!

Past AMDA Webinars

Stronger Together: Mental Health, Grief, and Caregiving in Pompe Disease

Stronger Together: Mental Health, Grief, and Caregiving in Pompe Disease

Webinar DetailsTitle: Stronger Together: Mental Health, Grief, and Caregiving in Pompe Disease Date: Monday, November 9, 2026 Speaker:Kendra J. Bjoraker, Ph.D., L.P. Webinar Overview:Pompe disease is a rare lysosomal storage disease, but living with it affects far...

read more
Biomarkers of Central Nervous System Involvement in Pome Disease

Biomarkers of Central Nervous System Involvement in Pome Disease

Title: Biomarkers of Central Nervous System Involvement in Pompe Disease: New Learnings
Date: Thursday, September 24, 2026
Time: 10 a.m. CT / 11 a.m. ET
Speaker:
Kristen Hagarty-Waite, PhD, RDN, LDN

Summary:
Central nervous system (CNS) manifestations persist in patients with Pompe disease, despite enzyme replacement therapy, as current formulations cannot cross the blood brain barrier. Plasma glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) have emerged as biomarkers to monitor CNS involvement in Pompe disease, particularly for those with the infantile-onset phenotype. In this presentation, we will share our learnings, so far, regarding biomarkers of CNS involvement.

read more
What Do Your Pompe Test Results Really Mean?

What Do Your Pompe Test Results Really Mean?

Title: What Do Your Pompe Test Results Really Mean? The Evolution of Pompe Diagnostics: Past, Present, and Future
Date: Thursday, August 20, 2026
Time: 1 p.m. CT / 2 p.m. ET
Speaker:
Deeksha Bali, PhD, FACMG
Summary:
This webinar examines Pompe disease diagnosis in the newborn screening era, drawing on lessons learned since implementation and the growing challenge of novel variants identified each year. It highlights the role of CRIM testing, GAA enzyme and mutation analysis, and urine Hex4 biomarker testing in achieving early, accurate diagnosis. The talk underscores an urgent need for a validated, disease-specific functional assay to characterize variants of unknown significance and support their reclassification, benefiting newly diagnosed patients. It also points to the promise of understanding Pompe disease’s molecular mechanisms to predict disease onset and progression and guide treatment decisions, an unmet need for patients identified through newborn screening.

read more